3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
CNS
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
Breast
1
Conditions
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Interventions
Specimen Handling
36
Magnetic Resonance Spectroscopy
31
Cyclophosphamide
26
Doxorubicin
23
Biopsy
22
pembrolizumab
21
Temozolomide
21
X-Rays
17
Radiotherapy
17
Radiation
16
Nivolumab
13
atezolizumab
12
Vincristine
12
Phantoms, Imaging
12
Irinotecan
12
Ifosfamide
12
Gemcitabine
12
fludarabine
11
cabozantinib
10
liposomal doxorubicin
8
Surgical Procedures, Operative
8
Ipilimumab
8
Etoposide
8
Bevacizumab
8
Paclitaxel
7
Immunoglobulin G
7
Carboplatin
7
palbociclib
6
olaparib
6
fludarabine phosphate
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
CLR1404
×
Sarcoma
×
90 days
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled